Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Despite weight loss and glycemic control, experts caution that type 2 diabetes remission is not a cure and that pancreatic ...

Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Terns Pharmaceuticals, Inc.’s TERN share price has surged by 14.97%, which has investors questioning if this is right time to ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) has been given an average rating of “Buy” by the eight research ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 ... small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid ...

A new study suggests that semaglutide, a drug commonly used to treat diabetes, may help protect the brain from the effects of ...

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and ...